Citius Oncology shares are trading higher. The company issued a commercial update on the U.S. launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.
Tenx Keane Acquisition +1.53%
Tenx Keane Acquisition CTOR | 0.67 | +1.53% |
Citius Oncology shares are trading higher. The company issued a commercial update on the U.S. launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.
